223
Participants
Start Date
November 4, 2021
Primary Completion Date
May 30, 2025
Study Completion Date
June 5, 2026
Darolutamide (BAY1841788, Nubeqa)
300 mg per tablet, oral administration with food
ADT
LHRH agonist/antagonist or orchiectomy
Mount Sinai Doctors - Faculty Practice, New York
Mount Sinai Faculty Practice Associates, New York
Associated Medical Professionals of NY Syracuse, Syracuse
MidLantic Urology - Bala Cynwyd, Bala-Cynwyd
UM Greenebaum Comprehensive Cancer Center, Baltimore
Inova Schar Cancer Institute, Fairfax
Carolina Urological Research Center, Myrtle Beach
Brigham and Women's Hospital (BWH) - Surgery Urology, Atlanta
Piedmont Cancer Institute - Atlanta, Atlanta
Urology Centers of Alabama, PC, Homewood
Urology Associates, PC, Nashville
Columbus Prostate Cancer Center / Radiation Oncology Clinic, Gahanna
The Urology Group - Norwood Surgery Center, Cincinnati
Michigan Institute of Urology - Troy - Town Center Building, Troy
VA Ann Arbor Healthcare System, Ann Arbor
Barbara Ann Karmanos Cancer Institute - Detroit Headquarters, Detroit
Northwestern Medicine - Urology, Chicago
Northwestern University's Feinberg School of Medicine, Chicago
AMR - Kansas City, Kansas City
GU Research Network, LLC - Oncology radiology, Omaha
XCancer Omaha, Omaha
Houston Methodist Research Institute, Houston
Arizona Urology Specialists - Tucson - W Orange Grove, Tucson
New Mexico Cancer Center - Albuquerque, Albuquerque
Tower Urology, Los Angeles
Providence Saint John's Cancer Institute, Santa Monica
UC San Diego Health - Moores Cancer Center, San Diego
UCI Health Center for Urological Care, Orange
Spokane Urology PS, Spokane
New Jersey Urology - Clifton, Clifton
New Jersey Urology - Voorhees, Voorhees Township
Lead Sponsor
Bayer
INDUSTRY